Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Gland Pharma (NSE:GLAND, BOM:543245) is planning to invest up to 20 billion Indian rupees (or 1.64 billion yuan) in Indian mutual funds and government or corporate bonds.
Investments will be in low-risk mutual funds and bond products in accordance with the principle of strict risk control, according to a Tuesday filing with the Shanghai bourse.
The authorization is valid until March 31, 2027.
Fosun Pharma's shares fell nearly 2% in Hong Kong and almost 1% in Shanghai recently.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。